Charting the Course: Sequencing Immunotherapy for Multiple Myeloma

M Mohan, O Van Oekelen, OS Akhtar… - American Society of …, 2024 - ascopubs.org
Multiple chimeric antigen receptor (CAR) T-cell and bispecific antibody (bsAb) therapies
have been approved, demonstrating impressive clinical efficacy in relapsed/refractory …

International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies …

P Rodriguez-Otero, S Usmani, AD Cohen… - The Lancet …, 2024 - thelancet.com
Multiple myeloma remains an incurable disease, despite the development of numerous drug
classes and combinations that have contributed to improved overall survival …

Real-world safety and Health care resource utilization of teclistamab under an outpatient model for step-up dosing administration

TB Sandahl, SA Soefje, R Fonseca… - JCO Oncology …, 2024 - ascopubs.org
PURPOSE Teclistamab is initiated with a step-up dosing (SUD) schedule to mitigate the risk
of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity …

[HTML][HTML] Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy

M Wang, C Wang, J Deng, H Wang, C Sun… - Frontiers in Bioscience …, 2024 - imrpress.com
The treatment options for multiple myeloma (MM) have undergone significant transformation
with the advent of immunotherapy. Novel therapies that focus on tumor antigens now drive …

[PDF][PDF] Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review

B Derman, C Tan, I Steinfield, FR Wilson, D Lin, B Wu… - 2024 - preprints.org
Teclistamab (TEC) is the first B-cell maturation antigen-directed bispecific antibody
approved by the European Medicines Agency and Food and Drug Administration for triple …